Aura Biosciences, Inc. (NASDAQ:AURA – Get Rating) saw a significant increase in short interest in April. As of April 30th, there was short interest totalling 642,500 shares, an increase of 23.6% from the April 15th total of 519,900 shares. Approximately 3.6% of the shares of the company are short sold. Based on an average trading volume of 37,900 shares, the days-to-cover ratio is currently 17.0 days.
Several institutional investors have recently bought and sold shares of the company. State Street Corp increased its position in shares of Aura Biosciences by 80.1% in the first quarter. State Street Corp now owns 84,982 shares of the company’s stock valued at $1,870,000 after buying an additional 37,797 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Aura Biosciences by 30.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 15,379 shares of the company’s stock valued at $339,000 after buying an additional 3,557 shares in the last quarter. Nantahala Capital Management LLC increased its position in shares of Aura Biosciences by 204.6% in the first quarter. Nantahala Capital Management LLC now owns 301,990 shares of the company’s stock valued at $6,644,000 after buying an additional 202,844 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Aura Biosciences by 1.0% in the first quarter. Vanguard Group Inc. now owns 228,633 shares of the company’s stock valued at $5,030,000 after buying an additional 2,375 shares in the last quarter. Finally, BlackRock Inc. increased its position in shares of Aura Biosciences by 15.2% in the first quarter. BlackRock Inc. now owns 275,027 shares of the company’s stock valued at $6,050,000 after buying an additional 36,244 shares in the last quarter. Institutional investors and hedge funds own 51.69% of the company’s stock.
Separately, Zacks Investment Research upgraded Aura Biosciences from a “sell” rating to a “hold” rating in a research report on Thursday, May 12th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $33.25.
Shares of AURA stock opened at $16.32 on Tuesday. Aura Biosciences has a twelve month low of $13.50 and a twelve month high of $26.16. The firm’s 50 day moving average is $19.06.
Aura Biosciences (NASDAQ:AURA – Get Rating) last posted its quarterly earnings data on Thursday, May 12th. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.14. As a group, equities analysts predict that Aura Biosciences will post -2.03 EPS for the current year.
Aura Biosciences Company Profile (Get Rating)
Aura Biosciences, Inc operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.